Evaluation of Oral PCA Device - PCoA™ Acute
Launched by DOSENTRX LTD. · Apr 27, 2017
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Operative procedure with at least 3 days' hospital stay.
- • 2. Planned post-operative pain therapy with oral medication using a strong opioid.
- • 3. No contra-indication for opioid therapy.
- • 4. No contra-indication for oral pain therapy.
- • 5. Patient was able to understand and complete the questionnaire.
- • 6. Patient signed an informed consent form.
- Exclusion Criteria:
- • 1. Opioid or drug addiction. 2. Opioid intolerance. 3. Pain therapy using IV PCA or infusion. 4. Rejection of opioid therapy. 5. Not able to swallow medicine.
- • -
About Dosentrx Ltd.
Dosentrx Ltd. is an innovative biotechnology company focused on advancing therapeutic solutions through cutting-edge research and development. Specializing in the design and delivery of novel drug formulations, Dosentrx is committed to addressing unmet medical needs across various therapeutic areas. With a strong emphasis on clinical excellence and regulatory compliance, the company collaborates with healthcare professionals and research institutions to conduct rigorous clinical trials that aim to enhance patient outcomes and improve quality of life. Through its dedication to scientific advancement and patient-centric approaches, Dosentrx Ltd. strives to contribute meaningfully to the evolving landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials